CN112384207B - 米托蒽醌脂质体治疗非霍奇金淋巴瘤的用途 - Google Patents
米托蒽醌脂质体治疗非霍奇金淋巴瘤的用途 Download PDFInfo
- Publication number
- CN112384207B CN112384207B CN201980046225.1A CN201980046225A CN112384207B CN 112384207 B CN112384207 B CN 112384207B CN 201980046225 A CN201980046225 A CN 201980046225A CN 112384207 B CN112384207 B CN 112384207B
- Authority
- CN
- China
- Prior art keywords
- mitoxantrone
- liposome
- subject
- pharmaceutical formulation
- injection
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 239000002502 liposome Substances 0.000 title claims abstract description 95
- 229960001156 mitoxantrone Drugs 0.000 title claims abstract description 82
- KKZJGLLVHKMTCM-UHFFFAOYSA-N mitoxantrone Chemical compound O=C1C2=C(O)C=CC(O)=C2C(=O)C2=C1C(NCCNCCO)=CC=C2NCCNCCO KKZJGLLVHKMTCM-UHFFFAOYSA-N 0.000 title claims abstract description 82
- 208000015914 Non-Hodgkin lymphomas Diseases 0.000 title abstract description 22
- 239000008194 pharmaceutical composition Substances 0.000 claims abstract description 52
- 208000027190 Peripheral T-cell lymphomas Diseases 0.000 claims abstract description 46
- 208000031672 T-Cell Peripheral Lymphoma Diseases 0.000 claims abstract description 46
- 239000003814 drug Substances 0.000 claims abstract description 46
- 208000020968 mature T-cell and NK-cell non-Hodgkin lymphoma Diseases 0.000 claims abstract description 38
- 206010025323 Lymphomas Diseases 0.000 claims abstract description 37
- 206010012818 diffuse large B-cell lymphoma Diseases 0.000 claims abstract description 34
- 208000031671 Large B-Cell Diffuse Lymphoma Diseases 0.000 claims abstract description 32
- 230000000259 anti-tumor effect Effects 0.000 claims abstract description 9
- 238000004519 manufacturing process Methods 0.000 claims abstract description 8
- 229940124597 therapeutic agent Drugs 0.000 claims abstract description 5
- 238000011282 treatment Methods 0.000 claims description 44
- 238000000034 method Methods 0.000 claims description 36
- 150000003904 phospholipids Chemical class 0.000 claims description 28
- 239000002245 particle Substances 0.000 claims description 20
- 230000036760 body temperature Effects 0.000 claims description 16
- 239000000243 solution Substances 0.000 claims description 16
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 claims description 14
- 239000003276 histone deacetylase inhibitor Substances 0.000 claims description 14
- 229920001223 polyethylene glycol Polymers 0.000 claims description 14
- 239000002202 Polyethylene glycol Substances 0.000 claims description 12
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 claims description 11
- 238000001990 intravenous administration Methods 0.000 claims description 11
- 239000000787 lecithin Substances 0.000 claims description 11
- 229940067606 lecithin Drugs 0.000 claims description 11
- 235000010445 lecithin Nutrition 0.000 claims description 11
- 239000008354 sodium chloride injection Substances 0.000 claims description 10
- 229940121372 histone deacetylase inhibitor Drugs 0.000 claims description 9
- 239000007924 injection Substances 0.000 claims description 9
- 229940090044 injection Drugs 0.000 claims description 9
- 238000002347 injection Methods 0.000 claims description 9
- LVNGJLRDBYCPGB-UHFFFAOYSA-N 1,2-distearoylphosphatidylethanolamine Chemical class CCCCCCCCCCCCCCCCCC(=O)OCC(COP([O-])(=O)OCC[NH3+])OC(=O)CCCCCCCCCCCCCCCCC LVNGJLRDBYCPGB-UHFFFAOYSA-N 0.000 claims description 8
- PZNPLUBHRSSFHT-RRHRGVEJSA-N 1-hexadecanoyl-2-octadecanoyl-sn-glycero-3-phosphocholine Chemical class CCCCCCCCCCCCCCCCCC(=O)O[C@@H](COP([O-])(=O)OCC[N+](C)(C)C)COC(=O)CCCCCCCCCCCCCCC PZNPLUBHRSSFHT-RRHRGVEJSA-N 0.000 claims description 8
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Chemical compound OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims description 8
- 229940093181 glucose injection Drugs 0.000 claims description 8
- 150000002500 ions Chemical class 0.000 claims description 8
- 235000012000 cholesterol Nutrition 0.000 claims description 7
- 230000007704 transition Effects 0.000 claims description 7
- 238000010253 intravenous injection Methods 0.000 claims description 6
- JQWAHKMIYCERGA-UHFFFAOYSA-N (2-nonanoyloxy-3-octadeca-9,12-dienoyloxypropoxy)-[2-(trimethylazaniumyl)ethyl]phosphinate Chemical class CCCCCCCCC(=O)OC(COP([O-])(=O)CC[N+](C)(C)C)COC(=O)CCCCCCCC=CCC=CCCCCC JQWAHKMIYCERGA-UHFFFAOYSA-N 0.000 claims description 5
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 claims description 5
- WTJKGGKOPKCXLL-RRHRGVEJSA-N phosphatidylcholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCC=CCCCCCCCC WTJKGGKOPKCXLL-RRHRGVEJSA-N 0.000 claims description 5
- 239000008355 dextrose injection Substances 0.000 claims description 4
- 239000004480 active ingredient Substances 0.000 claims description 3
- 239000002244 precipitate Substances 0.000 claims description 3
- PYKYMHQGRFAEBM-UHFFFAOYSA-N anthraquinone Natural products CCC(=O)c1c(O)c2C(=O)C3C(C=CC=C3O)C(=O)c2cc1CC(=O)OC PYKYMHQGRFAEBM-UHFFFAOYSA-N 0.000 claims description 2
- 150000004056 anthraquinones Chemical class 0.000 claims description 2
- 238000009472 formulation Methods 0.000 claims description 2
- 239000007927 intramuscular injection Substances 0.000 claims description 2
- 238000010255 intramuscular injection Methods 0.000 claims description 2
- 239000000203 mixture Substances 0.000 claims description 2
- 239000007929 subcutaneous injection Substances 0.000 claims description 2
- 238000010254 subcutaneous injection Methods 0.000 claims description 2
- 238000011200 topical administration Methods 0.000 claims description 2
- 239000013543 active substance Substances 0.000 claims 2
- 239000003226 mitogen Substances 0.000 claims 1
- 238000011519 second-line treatment Methods 0.000 claims 1
- 229910021653 sulphate ion Inorganic materials 0.000 claims 1
- 239000002246 antineoplastic agent Substances 0.000 abstract description 5
- 229940041181 antineoplastic drug Drugs 0.000 abstract description 2
- 229940079593 drug Drugs 0.000 description 32
- 229960005420 etoposide Drugs 0.000 description 31
- AOJJSUZBOXZQNB-TZSSRYMLSA-N Doxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 description 28
- VJJPUSNTGOMMGY-MRVIYFEKSA-N etoposide Chemical compound COC1=C(O)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3[C@@H](O[C@H]3[C@@H]([C@@H](O)[C@@H]4O[C@H](C)OC[C@H]4O3)O)[C@@H]3[C@@H]2C(OC3)=O)=C1 VJJPUSNTGOMMGY-MRVIYFEKSA-N 0.000 description 26
- 229960004618 prednisone Drugs 0.000 description 20
- XOFYZVNMUHMLCC-ZPOLXVRWSA-N prednisone Chemical compound O=C1C=C[C@]2(C)[C@H]3C(=O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 XOFYZVNMUHMLCC-ZPOLXVRWSA-N 0.000 description 20
- OGWKCGZFUXNPDA-XQKSVPLYSA-N vincristine Chemical compound C([N@]1C[C@@H](C[C@]2(C(=O)OC)C=3C(=CC4=C([C@]56[C@H]([C@@]([C@H](OC(C)=O)[C@]7(CC)C=CCN([C@H]67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)C[C@@](C1)(O)CC)CC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-XQKSVPLYSA-N 0.000 description 20
- 229960004528 vincristine Drugs 0.000 description 20
- OGWKCGZFUXNPDA-UHFFFAOYSA-N vincristine Natural products C1C(CC)(O)CC(CC2(C(=O)OC)C=3C(=CC4=C(C56C(C(C(OC(C)=O)C7(CC)C=CCN(C67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)CN1CCC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-UHFFFAOYSA-N 0.000 description 20
- 229960004397 cyclophosphamide Drugs 0.000 description 19
- 229960003957 dexamethasone Drugs 0.000 description 17
- UREBDLICKHMUKA-CXSFZGCWSA-N dexamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-CXSFZGCWSA-N 0.000 description 17
- 206010028980 Neoplasm Diseases 0.000 description 15
- DQLATGHUWYMOKM-UHFFFAOYSA-L cisplatin Chemical compound N[Pt](N)(Cl)Cl DQLATGHUWYMOKM-UHFFFAOYSA-L 0.000 description 15
- 229960004316 cisplatin Drugs 0.000 description 15
- CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 description 14
- 229960004679 doxorubicin Drugs 0.000 description 14
- 229960005277 gemcitabine Drugs 0.000 description 14
- 238000002360 preparation method Methods 0.000 description 12
- 229960004562 carboplatin Drugs 0.000 description 10
- 190000008236 carboplatin Chemical compound 0.000 description 10
- SDUQYLNIPVEERB-QPPQHZFASA-N gemcitabine Chemical compound O=C1N=C(N)C=CN1[C@H]1C(F)(F)[C@H](O)[C@@H](CO)O1 SDUQYLNIPVEERB-QPPQHZFASA-N 0.000 description 10
- 231100000226 haematotoxicity Toxicity 0.000 description 10
- 201000011510 cancer Diseases 0.000 description 9
- 230000000694 effects Effects 0.000 description 9
- HOMGKSMUEGBAAB-UHFFFAOYSA-N ifosfamide Chemical compound ClCCNP1(=O)OCCCN1CCCl HOMGKSMUEGBAAB-UHFFFAOYSA-N 0.000 description 9
- 229960001101 ifosfamide Drugs 0.000 description 9
- 206010042971 T-cell lymphoma Diseases 0.000 description 8
- 208000027585 T-cell non-Hodgkin lymphoma Diseases 0.000 description 8
- 230000009467 reduction Effects 0.000 description 8
- 238000011156 evaluation Methods 0.000 description 7
- 238000001802 infusion Methods 0.000 description 7
- -1 povidone modified distearoyl phosphatidylethanolamine Chemical class 0.000 description 7
- UHDGCWIWMRVCDJ-CCXZUQQUSA-N Cytarabine Chemical compound O=C1N=C(N)C=CN1[C@H]1[C@@H](O)[C@H](O)[C@@H](CO)O1 UHDGCWIWMRVCDJ-CCXZUQQUSA-N 0.000 description 6
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 6
- 210000004369 blood Anatomy 0.000 description 6
- 239000008280 blood Substances 0.000 description 6
- 229960000684 cytarabine Drugs 0.000 description 6
- 210000000440 neutrophil Anatomy 0.000 description 6
- 239000000825 pharmaceutical preparation Substances 0.000 description 6
- 238000011269 treatment regimen Methods 0.000 description 6
- JLPULHDHAOZNQI-ZTIMHPMXSA-N 1-hexadecanoyl-2-(9Z,12Z-octadecadienoyl)-sn-glycero-3-phosphocholine Chemical class CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCC\C=C/C\C=C/CCCCC JLPULHDHAOZNQI-ZTIMHPMXSA-N 0.000 description 5
- 108010006654 Bleomycin Proteins 0.000 description 5
- 229960001561 bleomycin Drugs 0.000 description 5
- OYVAGSVQBOHSSS-UAPAGMARSA-O bleomycin A2 Chemical compound N([C@H](C(=O)N[C@H](C)[C@@H](O)[C@H](C)C(=O)N[C@@H]([C@H](O)C)C(=O)NCCC=1SC=C(N=1)C=1SC=C(N=1)C(=O)NCCC[S+](C)C)[C@@H](O[C@H]1[C@H]([C@@H](O)[C@H](O)[C@H](CO)O1)O[C@@H]1[C@H]([C@@H](OC(N)=O)[C@H](O)[C@@H](CO)O1)O)C=1N=CNC=1)C(=O)C1=NC([C@H](CC(N)=O)NC[C@H](N)C(N)=O)=NC(N)=C1C OYVAGSVQBOHSSS-UAPAGMARSA-O 0.000 description 5
- 238000009104 chemotherapy regimen Methods 0.000 description 5
- ZNEWHQLOPFWXOF-UHFFFAOYSA-N coenzyme M Chemical compound OS(=O)(=O)CCS ZNEWHQLOPFWXOF-UHFFFAOYSA-N 0.000 description 5
- 230000007423 decrease Effects 0.000 description 5
- 239000003085 diluting agent Substances 0.000 description 5
- 239000011521 glass Substances 0.000 description 5
- 229940099578 hydrogenated soybean lecithin Drugs 0.000 description 5
- 229960004635 mesna Drugs 0.000 description 5
- 230000002093 peripheral effect Effects 0.000 description 5
- 238000002560 therapeutic procedure Methods 0.000 description 5
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 4
- 239000002177 L01XE27 - Ibrutinib Substances 0.000 description 4
- 210000001744 T-lymphocyte Anatomy 0.000 description 4
- 238000004458 analytical method Methods 0.000 description 4
- 229940045799 anthracyclines and related substance Drugs 0.000 description 4
- 238000004820 blood count Methods 0.000 description 4
- 238000009096 combination chemotherapy Methods 0.000 description 4
- 201000010099 disease Diseases 0.000 description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 4
- 229960001507 ibrutinib Drugs 0.000 description 4
- XYFPWWZEPKGCCK-GOSISDBHSA-N ibrutinib Chemical compound C1=2C(N)=NC=NC=2N([C@H]2CN(CCC2)C(=O)C=C)N=C1C(C=C1)=CC=C1OC1=CC=CC=C1 XYFPWWZEPKGCCK-GOSISDBHSA-N 0.000 description 4
- UWKQSNNFCGGAFS-XIFFEERXSA-N irinotecan Chemical compound C1=C2C(CC)=C3CN(C(C4=C([C@@](C(=O)OC4)(O)CC)C=4)=O)C=4C3=NC2=CC=C1OC(=O)N(CC1)CCC1N1CCCCC1 UWKQSNNFCGGAFS-XIFFEERXSA-N 0.000 description 4
- 210000000265 leukocyte Anatomy 0.000 description 4
- 229960001756 oxaliplatin Drugs 0.000 description 4
- DWAFYCQODLXJNR-BNTLRKBRSA-L oxaliplatin Chemical compound O1C(=O)C(=O)O[Pt]11N[C@@H]2CCCC[C@H]2N1 DWAFYCQODLXJNR-BNTLRKBRSA-L 0.000 description 4
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 4
- 230000000306 recurrent effect Effects 0.000 description 4
- 238000011160 research Methods 0.000 description 4
- 239000000126 substance Substances 0.000 description 4
- ASWBNKHCZGQVJV-UHFFFAOYSA-N (3-hexadecanoyloxy-2-hydroxypropyl) 2-(trimethylazaniumyl)ethyl phosphate Chemical compound CCCCCCCCCCCCCCCC(=O)OCC(O)COP([O-])(=O)OCC[N+](C)(C)C ASWBNKHCZGQVJV-UHFFFAOYSA-N 0.000 description 3
- 206010067484 Adverse reaction Diseases 0.000 description 3
- 101001105486 Homo sapiens Proteasome subunit alpha type-7 Proteins 0.000 description 3
- OFOBLEOULBTSOW-UHFFFAOYSA-N Malonic acid Chemical compound OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 3
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 3
- 102100021201 Proteasome subunit alpha type-7 Human genes 0.000 description 3
- 230000002411 adverse Effects 0.000 description 3
- 230000006838 adverse reaction Effects 0.000 description 3
- 238000010322 bone marrow transplantation Methods 0.000 description 3
- 238000002512 chemotherapy Methods 0.000 description 3
- 229950009221 chidamide Drugs 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 238000009093 first-line therapy Methods 0.000 description 3
- 229960004768 irinotecan Drugs 0.000 description 3
- 230000036210 malignancy Effects 0.000 description 3
- 229960000485 methotrexate Drugs 0.000 description 3
- ZAHQPTJLOCWVPG-UHFFFAOYSA-N mitoxantrone dihydrochloride Chemical compound Cl.Cl.O=C1C2=C(O)C=CC(O)=C2C(=O)C2=C1C(NCCNCCO)=CC=C2NCCNCCO ZAHQPTJLOCWVPG-UHFFFAOYSA-N 0.000 description 3
- 229960004169 mitoxantrone hydrochloride Drugs 0.000 description 3
- WXHHICFWKXDFOW-BJMVGYQFSA-N n-(2-amino-5-fluorophenyl)-4-[[[(e)-3-pyridin-3-ylprop-2-enoyl]amino]methyl]benzamide Chemical compound NC1=CC=C(F)C=C1NC(=O)C(C=C1)=CC=C1CNC(=O)\C=C\C1=CC=CN=C1 WXHHICFWKXDFOW-BJMVGYQFSA-N 0.000 description 3
- 210000000822 natural killer cell Anatomy 0.000 description 3
- 229960004641 rituximab Drugs 0.000 description 3
- OHRURASPPZQGQM-GCCNXGTGSA-N romidepsin Chemical compound O1C(=O)[C@H](C(C)C)NC(=O)C(=C/C)/NC(=O)[C@H]2CSSCC\C=C\[C@@H]1CC(=O)N[C@H](C(C)C)C(=O)N2 OHRURASPPZQGQM-GCCNXGTGSA-N 0.000 description 3
- 229960003452 romidepsin Drugs 0.000 description 3
- OHRURASPPZQGQM-UHFFFAOYSA-N romidepsin Natural products O1C(=O)C(C(C)C)NC(=O)C(=CC)NC(=O)C2CSSCCC=CC1CC(=O)NC(C(C)C)C(=O)N2 OHRURASPPZQGQM-UHFFFAOYSA-N 0.000 description 3
- 108010091666 romidepsin Proteins 0.000 description 3
- 238000011476 stem cell transplantation Methods 0.000 description 3
- 230000009885 systemic effect Effects 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- 206010043554 thrombocytopenia Diseases 0.000 description 3
- BINQFWQYTCAARG-UHFFFAOYSA-N 1-(1-acetylindolizin-3-yl)ethanone Chemical compound C1=CC=CC2=C(C(=O)C)C=C(C(C)=O)N21 BINQFWQYTCAARG-UHFFFAOYSA-N 0.000 description 2
- UEJJHQNACJXSKW-UHFFFAOYSA-N 2-(2,6-dioxopiperidin-3-yl)-1H-isoindole-1,3(2H)-dione Chemical compound O=C1C2=CC=CC=C2C(=O)N1C1CCC(=O)NC1=O UEJJHQNACJXSKW-UHFFFAOYSA-N 0.000 description 2
- 208000031261 Acute myeloid leukaemia Diseases 0.000 description 2
- 108020004414 DNA Proteins 0.000 description 2
- 208000016937 Extranodal nasal NK/T cell lymphoma Diseases 0.000 description 2
- GHASVSINZRGABV-UHFFFAOYSA-N Fluorouracil Chemical compound FC1=CNC(=O)NC1=O GHASVSINZRGABV-UHFFFAOYSA-N 0.000 description 2
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 2
- 239000004471 Glycine Substances 0.000 description 2
- 208000017604 Hodgkin disease Diseases 0.000 description 2
- 208000021519 Hodgkin lymphoma Diseases 0.000 description 2
- 208000010747 Hodgkins lymphoma Diseases 0.000 description 2
- 101000611183 Homo sapiens Tumor necrosis factor Proteins 0.000 description 2
- 208000025205 Mantle-Cell Lymphoma Diseases 0.000 description 2
- 208000033776 Myeloid Acute Leukemia Diseases 0.000 description 2
- FVJZSBGHRPJMMA-IOLBBIBUSA-N PG(18:0/18:0) Chemical class CCCCCCCCCCCCCCCCCC(=O)OC[C@H](COP(O)(=O)OC[C@@H](O)CO)OC(=O)CCCCCCCCCCCCCCCCC FVJZSBGHRPJMMA-IOLBBIBUSA-N 0.000 description 2
- 229910019142 PO4 Inorganic materials 0.000 description 2
- KMSKQZKKOZQFFG-HSUXVGOQSA-N Pirarubicin Chemical compound O([C@H]1[C@@H](N)C[C@@H](O[C@H]1C)O[C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1CCCCO1 KMSKQZKKOZQFFG-HSUXVGOQSA-N 0.000 description 2
- 102100023884 Probable ribonuclease ZC3H12D Human genes 0.000 description 2
- 206010060862 Prostate cancer Diseases 0.000 description 2
- 208000000236 Prostatic Neoplasms Diseases 0.000 description 2
- 229930006000 Sucrose Natural products 0.000 description 2
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 2
- 206010066901 Treatment failure Diseases 0.000 description 2
- JXLYSJRDGCGARV-WWYNWVTFSA-N Vinblastine Natural products O=C(O[C@H]1[C@](O)(C(=O)OC)[C@@H]2N(C)c3c(cc(c(OC)c3)[C@]3(C(=O)OC)c4[nH]c5c(c4CCN4C[C@](O)(CC)C[C@H](C3)C4)cccc5)[C@@]32[C@H]2[C@@]1(CC)C=CCN2CC3)C JXLYSJRDGCGARV-WWYNWVTFSA-N 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 239000008186 active pharmaceutical agent Substances 0.000 description 2
- 239000002671 adjuvant Substances 0.000 description 2
- BFNBIHQBYMNNAN-UHFFFAOYSA-N ammonium sulfate Chemical compound N.N.OS(O)(=O)=O BFNBIHQBYMNNAN-UHFFFAOYSA-N 0.000 description 2
- 229910052921 ammonium sulfate Inorganic materials 0.000 description 2
- 235000011130 ammonium sulphate Nutrition 0.000 description 2
- 206010002449 angioimmunoblastic T-cell lymphoma Diseases 0.000 description 2
- 210000003719 b-lymphocyte Anatomy 0.000 description 2
- AFTOJIAPXHGBGH-UHFFFAOYSA-N bis(2-oxopyridin-1-yl) carbonate Chemical compound C1=CC=CC(=O)N1OC(=O)ON1C=CC=CC1=O AFTOJIAPXHGBGH-UHFFFAOYSA-N 0.000 description 2
- 210000001185 bone marrow Anatomy 0.000 description 2
- 150000001841 cholesterols Chemical class 0.000 description 2
- 238000011284 combination treatment Methods 0.000 description 2
- DMSZORWOGDLWGN-UHFFFAOYSA-N ctk1a3526 Chemical compound NP(N)(N)=O DMSZORWOGDLWGN-UHFFFAOYSA-N 0.000 description 2
- IMBXRZKCLVBLBH-OGYJWPHRSA-N cvp protocol Chemical compound ClCCN(CCCl)P1(=O)NCCCO1.O=C1C=C[C@]2(C)[C@H]3C(=O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1.C([C@H](C[C@]1(C(=O)OC)C=2C(=C3C([C@]45[C@H]([C@@]([C@H](OC(C)=O)[C@]6(CC)C=CCN([C@H]56)CC4)(O)C(=O)OC)N3C=O)=CC=2)OC)C[C@@](C2)(O)CC)N2CCC2=C1NC1=CC=CC=C21 IMBXRZKCLVBLBH-OGYJWPHRSA-N 0.000 description 2
- 229960000975 daunorubicin Drugs 0.000 description 2
- GNGACRATGGDKBX-UHFFFAOYSA-N dihydroxyacetone phosphate Chemical compound OCC(=O)COP(O)(O)=O GNGACRATGGDKBX-UHFFFAOYSA-N 0.000 description 2
- 238000010494 dissociation reaction Methods 0.000 description 2
- 230000005593 dissociations Effects 0.000 description 2
- 229940042317 doxorubicin liposome Drugs 0.000 description 2
- 239000000890 drug combination Substances 0.000 description 2
- 210000003743 erythrocyte Anatomy 0.000 description 2
- 229960002949 fluorouracil Drugs 0.000 description 2
- 102000057041 human TNF Human genes 0.000 description 2
- 238000002513 implantation Methods 0.000 description 2
- 239000004615 ingredient Substances 0.000 description 2
- 230000003902 lesion Effects 0.000 description 2
- 150000002632 lipids Chemical class 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 2
- 239000010452 phosphate Substances 0.000 description 2
- 229960001221 pirarubicin Drugs 0.000 description 2
- 229960000214 pralatrexate Drugs 0.000 description 2
- OGSBUKJUDHAQEA-WMCAAGNKSA-N pralatrexate Chemical compound C1=NC2=NC(N)=NC(N)=C2N=C1CC(CC#C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 OGSBUKJUDHAQEA-WMCAAGNKSA-N 0.000 description 2
- 238000003860 storage Methods 0.000 description 2
- 239000005720 sucrose Substances 0.000 description 2
- 229960003433 thalidomide Drugs 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 2
- 210000004881 tumor cell Anatomy 0.000 description 2
- 229960003048 vinblastine Drugs 0.000 description 2
- JXLYSJRDGCGARV-XQKSVPLYSA-N vincaleukoblastine Chemical compound C([C@@H](C[C@]1(C(=O)OC)C=2C(=CC3=C([C@]45[C@H]([C@@]([C@H](OC(C)=O)[C@]6(CC)C=CCN([C@H]56)CC4)(O)C(=O)OC)N3C)C=2)OC)C[C@@](C2)(O)CC)N2CCC2=C1NC1=CC=CC=C21 JXLYSJRDGCGARV-XQKSVPLYSA-N 0.000 description 2
- ZCGNOLQNACZJCN-VMMOASCLSA-N (5ar,8ar,9r)-5-[[(2r,4ar,6r,7r,8r,8as)-7,8-dihydroxy-2-methyl-4,4a,6,7,8,8a-hexahydropyrano[3,2-d][1,3]dioxin-6-yl]oxy]-9-(4-hydroxy-3,5-dimethoxyphenyl)-5a,6,8a,9-tetrahydro-5h-[2]benzofuro[6,5-f][1,3]benzodioxol-8-one;n,3-bis(2-chloroethyl)-2-oxo-1,3,2$ Chemical compound [CH3-].[CH3-].[Pt+2].OC(=O)C1(C(O)=O)CCC1.ClCCNP1(=O)OCCCN1CCCl.COC1=C(O)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3C(O[C@H]3[C@@H]([C@@H](O)[C@@H]4O[C@H](C)OC[C@H]4O3)O)[C@@H]3[C@@H]2C(OC3)=O)=C1 ZCGNOLQNACZJCN-VMMOASCLSA-N 0.000 description 1
- BJEPYKJPYRNKOW-REOHCLBHSA-N (S)-malic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O BJEPYKJPYRNKOW-REOHCLBHSA-N 0.000 description 1
- KILNVBDSWZSGLL-KXQOOQHDSA-N 1,2-dihexadecanoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCCCCCCCCC KILNVBDSWZSGLL-KXQOOQHDSA-N 0.000 description 1
- NRJAVPSFFCBXDT-HUESYALOSA-N 1,2-distearoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCCCCCCCCCCC NRJAVPSFFCBXDT-HUESYALOSA-N 0.000 description 1
- VHRSUDSXCMQTMA-PJHHCJLFSA-N 6alpha-methylprednisolone Chemical compound C([C@@]12C)=CC(=O)C=C1[C@@H](C)C[C@@H]1[C@@H]2[C@@H](O)C[C@]2(C)[C@@](O)(C(=O)CO)CC[C@H]21 VHRSUDSXCMQTMA-PJHHCJLFSA-N 0.000 description 1
- 206010006187 Breast cancer Diseases 0.000 description 1
- 208000026310 Breast neoplasm Diseases 0.000 description 1
- 208000011691 Burkitt lymphomas Diseases 0.000 description 1
- DLGOEMSEDOSKAD-UHFFFAOYSA-N Carmustine Chemical compound ClCCNC(=O)N(N=O)CCCl DLGOEMSEDOSKAD-UHFFFAOYSA-N 0.000 description 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
- 206010009944 Colon cancer Diseases 0.000 description 1
- 208000001333 Colorectal Neoplasms Diseases 0.000 description 1
- LEVWYRKDKASIDU-QWWZWVQMSA-N D-cystine Chemical compound OC(=O)[C@H](N)CSSC[C@@H](N)C(O)=O LEVWYRKDKASIDU-QWWZWVQMSA-N 0.000 description 1
- 102000053602 DNA Human genes 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- GZDFHIJNHHMENY-UHFFFAOYSA-N Dimethyl dicarbonate Chemical compound COC(=O)OC(=O)OC GZDFHIJNHHMENY-UHFFFAOYSA-N 0.000 description 1
- 206010061818 Disease progression Diseases 0.000 description 1
- 206010014733 Endometrial cancer Diseases 0.000 description 1
- 206010014759 Endometrial neoplasm Diseases 0.000 description 1
- 208000002460 Enteropathy-Associated T-Cell Lymphoma Diseases 0.000 description 1
- 102000001554 Hemoglobins Human genes 0.000 description 1
- 108010054147 Hemoglobins Proteins 0.000 description 1
- 102000006947 Histones Human genes 0.000 description 1
- 108010033040 Histones Proteins 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 208000003623 Hypoalbuminemia Diseases 0.000 description 1
- 208000008839 Kidney Neoplasms Diseases 0.000 description 1
- FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 description 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 1
- 206010027476 Metastases Diseases 0.000 description 1
- 208000034578 Multiple myelomas Diseases 0.000 description 1
- 206010033128 Ovarian cancer Diseases 0.000 description 1
- 206010061535 Ovarian neoplasm Diseases 0.000 description 1
- 206010035226 Plasma cell myeloma Diseases 0.000 description 1
- 206010038389 Renal cancer Diseases 0.000 description 1
- 206010039491 Sarcoma Diseases 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 208000021712 Soft tissue sarcoma Diseases 0.000 description 1
- 208000010502 Subcutaneous panniculitis-like T-cell lymphoma Diseases 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-N Succinic acid Natural products OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 1
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
- 208000024313 Testicular Neoplasms Diseases 0.000 description 1
- 102000007537 Type II DNA Topoisomerases Human genes 0.000 description 1
- 108010046308 Type II DNA Topoisomerases Proteins 0.000 description 1
- 230000021736 acetylation Effects 0.000 description 1
- 238000006640 acetylation reaction Methods 0.000 description 1
- BJEPYKJPYRNKOW-UHFFFAOYSA-N alpha-hydroxysuccinic acid Natural products OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 1
- 150000001412 amines Chemical class 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 230000033115 angiogenesis Effects 0.000 description 1
- 208000022531 anorexia Diseases 0.000 description 1
- 230000006907 apoptotic process Effects 0.000 description 1
- NCNRHFGMJRPRSK-MDZDMXLPSA-N belinostat Chemical compound ONC(=O)\C=C\C1=CC=CC(S(=O)(=O)NC=2C=CC=CC=2)=C1 NCNRHFGMJRPRSK-MDZDMXLPSA-N 0.000 description 1
- 229960003094 belinostat Drugs 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 230000003115 biocidal effect Effects 0.000 description 1
- 238000001815 biotherapy Methods 0.000 description 1
- 230000005983 bone marrow dysfunction Effects 0.000 description 1
- KDYFGRWQOYBRFD-NUQCWPJISA-N butanedioic acid Chemical compound O[14C](=O)CC[14C](O)=O KDYFGRWQOYBRFD-NUQCWPJISA-N 0.000 description 1
- 229960005243 carmustine Drugs 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 230000022131 cell cycle Effects 0.000 description 1
- 230000024245 cell differentiation Effects 0.000 description 1
- 230000012292 cell migration Effects 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 230000000973 chemotherapeutic effect Effects 0.000 description 1
- 229940044683 chemotherapy drug Drugs 0.000 description 1
- 235000015165 citric acid Nutrition 0.000 description 1
- 238000002591 computed tomography Methods 0.000 description 1
- 230000001143 conditioned effect Effects 0.000 description 1
- 239000003433 contraceptive agent Substances 0.000 description 1
- 230000002254 contraceptive effect Effects 0.000 description 1
- 238000004132 cross linking Methods 0.000 description 1
- 229960003067 cystine Drugs 0.000 description 1
- 206010061428 decreased appetite Diseases 0.000 description 1
- 238000007865 diluting Methods 0.000 description 1
- 230000008034 disappearance Effects 0.000 description 1
- 230000005750 disease progression Effects 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 239000013583 drug formulation Substances 0.000 description 1
- 238000002651 drug therapy Methods 0.000 description 1
- 230000008451 emotion Effects 0.000 description 1
- 238000005538 encapsulation Methods 0.000 description 1
- 208000037902 enteropathy Diseases 0.000 description 1
- 238000002270 exclusion chromatography Methods 0.000 description 1
- 210000000245 forearm Anatomy 0.000 description 1
- 239000001530 fumaric acid Substances 0.000 description 1
- 235000011087 fumaric acid Nutrition 0.000 description 1
- 201000010536 head and neck cancer Diseases 0.000 description 1
- 208000014829 head and neck neoplasm Diseases 0.000 description 1
- 238000011134 hematopoietic stem cell transplantation Methods 0.000 description 1
- 230000036571 hydration Effects 0.000 description 1
- 238000006703 hydration reaction Methods 0.000 description 1
- 229910052739 hydrogen Inorganic materials 0.000 description 1
- 239000001257 hydrogen Substances 0.000 description 1
- 229920001477 hydrophilic polymer Polymers 0.000 description 1
- 208000008384 ileus Diseases 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 230000036512 infertility Effects 0.000 description 1
- 208000000509 infertility Diseases 0.000 description 1
- 231100000535 infertility Toxicity 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 208000028774 intestinal disease Diseases 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 230000009545 invasion Effects 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 201000010982 kidney cancer Diseases 0.000 description 1
- 230000002147 killing effect Effects 0.000 description 1
- 208000032839 leukemia Diseases 0.000 description 1
- 201000007270 liver cancer Diseases 0.000 description 1
- 208000014018 liver neoplasm Diseases 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 201000005202 lung cancer Diseases 0.000 description 1
- 208000020816 lung neoplasm Diseases 0.000 description 1
- 210000004324 lymphatic system Anatomy 0.000 description 1
- 230000000998 lymphohematopoietic effect Effects 0.000 description 1
- 210000003563 lymphoid tissue Anatomy 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
- 239000011976 maleic acid Substances 0.000 description 1
- 239000001630 malic acid Substances 0.000 description 1
- 235000011090 malic acid Nutrition 0.000 description 1
- 230000003211 malignant effect Effects 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 230000010534 mechanism of action Effects 0.000 description 1
- 201000001441 melanoma Diseases 0.000 description 1
- PIDANAQULIKBQS-RNUIGHNZSA-N meprednisone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@@H]2[C@@H]1[C@@H]1C[C@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)CC2=O PIDANAQULIKBQS-RNUIGHNZSA-N 0.000 description 1
- 229960001810 meprednisone Drugs 0.000 description 1
- 230000009401 metastasis Effects 0.000 description 1
- 229960004584 methylprednisolone Drugs 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 201000006417 multiple sclerosis Diseases 0.000 description 1
- 208000025189 neoplasm of testis Diseases 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 230000003204 osmotic effect Effects 0.000 description 1
- 235000006408 oxalic acid Nutrition 0.000 description 1
- KLAKIAVEMQMVBT-UHFFFAOYSA-N p-hydroxy-phenacyl alcohol Natural products OCC(=O)C1=CC=C(O)C=C1 KLAKIAVEMQMVBT-UHFFFAOYSA-N 0.000 description 1
- 210000005259 peripheral blood Anatomy 0.000 description 1
- 239000011886 peripheral blood Substances 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 229940069328 povidone Drugs 0.000 description 1
- 238000009597 pregnancy test Methods 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 230000002062 proliferating effect Effects 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 230000002685 pulmonary effect Effects 0.000 description 1
- 150000003254 radicals Chemical class 0.000 description 1
- 238000001959 radiotherapy Methods 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 238000005057 refrigeration Methods 0.000 description 1
- 238000009877 rendering Methods 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 229920006395 saturated elastomer Polymers 0.000 description 1
- 238000009094 second-line therapy Methods 0.000 description 1
- 238000009097 single-agent therapy Methods 0.000 description 1
- 238000003892 spreading Methods 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 230000002459 sustained effect Effects 0.000 description 1
- 238000002626 targeted therapy Methods 0.000 description 1
- 230000008685 targeting Effects 0.000 description 1
- 235000002906 tartaric acid Nutrition 0.000 description 1
- 239000011975 tartaric acid Substances 0.000 description 1
- 201000003120 testicular cancer Diseases 0.000 description 1
- 229940126585 therapeutic drug Drugs 0.000 description 1
- 230000004797 therapeutic response Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 238000000108 ultra-filtration Methods 0.000 description 1
- 238000002604 ultrasonography Methods 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/136—Amines having aromatic rings, e.g. ketamine, nortriptyline having the amino group directly attached to the aromatic ring, e.g. benzeneamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/127—Liposomes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/127—Liposomes
- A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes, liposomes coated with polymers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Dispersion Chemistry (AREA)
- Dermatology (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Description
Claims (36)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN2018107563157 | 2018-07-11 | ||
CN201810756315.7A CN110711178A (zh) | 2018-07-11 | 2018-07-11 | 盐酸米托蒽醌脂质体治疗非霍奇金淋巴瘤的用途 |
PCT/CN2019/095396 WO2020011189A1 (zh) | 2018-07-11 | 2019-07-10 | 米托蒽醌脂质体治疗非霍奇金淋巴瘤的用途 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN112384207A CN112384207A (zh) | 2021-02-19 |
CN112384207B true CN112384207B (zh) | 2024-02-06 |
Family
ID=69143169
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201810756315.7A Pending CN110711178A (zh) | 2018-07-11 | 2018-07-11 | 盐酸米托蒽醌脂质体治疗非霍奇金淋巴瘤的用途 |
CN201980046225.1A Active CN112384207B (zh) | 2018-07-11 | 2019-07-10 | 米托蒽醌脂质体治疗非霍奇金淋巴瘤的用途 |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201810756315.7A Pending CN110711178A (zh) | 2018-07-11 | 2018-07-11 | 盐酸米托蒽醌脂质体治疗非霍奇金淋巴瘤的用途 |
Country Status (12)
Country | Link |
---|---|
US (1) | US11583508B2 (zh) |
EP (1) | EP3821887B1 (zh) |
JP (1) | JP2021530489A (zh) |
KR (1) | KR20210031695A (zh) |
CN (2) | CN110711178A (zh) |
AU (1) | AU2019301101B2 (zh) |
BR (1) | BR112021000452A8 (zh) |
CA (1) | CA3105698A1 (zh) |
CU (1) | CU20210003A7 (zh) |
MX (1) | MX2020014107A (zh) |
SG (1) | SG11202013236XA (zh) |
WO (1) | WO2020011189A1 (zh) |
Families Citing this family (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP4098251A4 (en) * | 2020-02-10 | 2024-02-14 | Cspc Zhongqi Pharmaceutical Tech Shijiazhuang Co Ltd | USE OF A MITOXANTRONE HYDROCHLORIDE LIPOSOME FOR THE TREATMENT OF BREAST CANCER |
WO2021208842A1 (zh) * | 2020-04-13 | 2021-10-21 | 石药集团中奇制药技术(石家庄)有限公司 | 盐酸米托蒽醌脂质体的用途 |
US20230293454A1 (en) * | 2020-08-07 | 2023-09-21 | Cspc Zhongqi Pharmaceutical Technology (Shijiazhuang) Co., Ltd | Use of mitoxantrone hydrochloride liposome and pegaspargase |
WO2022042653A1 (zh) * | 2020-08-27 | 2022-03-03 | 石药集团中奇制药技术(石家庄)有限公司 | 盐酸米托蒽醌脂质体和环磷酰胺、长春新碱、强的松的用途 |
EP4324456A1 (en) * | 2021-04-16 | 2024-02-21 | CSPC Zhongqi Pharmaceutical Technology (Shijiazhuang) Co., Ltd. | Use of mitoxantrone hydrochloride liposome |
CN115400083A (zh) * | 2021-05-28 | 2022-11-29 | 石药集团中奇制药技术(石家庄)有限公司 | 盐酸米托蒽醌脂质体用于制备治疗晚期实体瘤的药物的用途 |
CN115770288A (zh) * | 2021-09-07 | 2023-03-10 | 石药集团中奇制药技术(石家庄)有限公司 | 米托蒽醌脂质体、硼替佐米和地塞米松治疗多发性骨髓瘤的用途 |
WO2023207931A1 (zh) * | 2022-04-26 | 2023-11-02 | 石药集团中奇制药技术(石家庄)有限公司 | 米托蒽醌脂质体联合抗血管生成靶向药治疗卵巢癌的用途 |
Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1469735A (zh) * | 2000-10-16 | 2004-01-21 | ����˹��ҩ�﹫˾ | 米托蒽醌的脂质体制剂 |
EP1537858A1 (en) * | 2003-12-04 | 2005-06-08 | Vectron Therapeutics AG | Drug delivery vehicles and uses thereof |
EP1538164A1 (en) * | 2003-12-04 | 2005-06-08 | Vectron Therapeutics AG | RGD targeting moiety its production and use |
JP2006063009A (ja) * | 2004-08-26 | 2006-03-09 | Konica Minolta Medical & Graphic Inc | 抗腫瘍リポソーム製剤およびその製造方法 |
CN101209243A (zh) * | 2006-12-29 | 2008-07-02 | 石药集团中奇制药技术(石家庄)有限公司 | 一种脂质体药物及其制备方法 |
CN103622909A (zh) * | 2012-08-28 | 2014-03-12 | 吉林大学 | 一种含心磷脂的脂质体新制剂及其在抗肿瘤药物中的应用 |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101229127B (zh) * | 2002-11-26 | 2012-10-10 | 吉里德科学公司 | 脂质体制剂 |
WO2009020590A1 (en) * | 2007-08-07 | 2009-02-12 | Celgene Corporation | Methods for treating lymphomas in certain patient populations and screening patients for said therapy |
CA2883443C (en) * | 2012-08-30 | 2021-01-12 | James Sacchettini | Compositions and methods for drug-sensitization or inhibition of a cancer cell |
-
2018
- 2018-07-11 CN CN201810756315.7A patent/CN110711178A/zh active Pending
-
2019
- 2019-07-10 CA CA3105698A patent/CA3105698A1/en active Pending
- 2019-07-10 WO PCT/CN2019/095396 patent/WO2020011189A1/zh unknown
- 2019-07-10 CN CN201980046225.1A patent/CN112384207B/zh active Active
- 2019-07-10 MX MX2020014107A patent/MX2020014107A/es unknown
- 2019-07-10 EP EP19833348.6A patent/EP3821887B1/en active Active
- 2019-07-10 CU CU2021000003A patent/CU20210003A7/es unknown
- 2019-07-10 KR KR1020217001296A patent/KR20210031695A/ko not_active Application Discontinuation
- 2019-07-10 AU AU2019301101A patent/AU2019301101B2/en active Active
- 2019-07-10 BR BR112021000452A patent/BR112021000452A8/pt unknown
- 2019-07-10 JP JP2021500673A patent/JP2021530489A/ja active Pending
- 2019-07-10 US US17/258,801 patent/US11583508B2/en active Active
- 2019-07-10 SG SG11202013236XA patent/SG11202013236XA/en unknown
Patent Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1469735A (zh) * | 2000-10-16 | 2004-01-21 | ����˹��ҩ�﹫˾ | 米托蒽醌的脂质体制剂 |
EP1537858A1 (en) * | 2003-12-04 | 2005-06-08 | Vectron Therapeutics AG | Drug delivery vehicles and uses thereof |
EP1538164A1 (en) * | 2003-12-04 | 2005-06-08 | Vectron Therapeutics AG | RGD targeting moiety its production and use |
JP2006063009A (ja) * | 2004-08-26 | 2006-03-09 | Konica Minolta Medical & Graphic Inc | 抗腫瘍リポソーム製剤およびその製造方法 |
CN101209243A (zh) * | 2006-12-29 | 2008-07-02 | 石药集团中奇制药技术(石家庄)有限公司 | 一种脂质体药物及其制备方法 |
CN103622909A (zh) * | 2012-08-28 | 2014-03-12 | 吉林大学 | 一种含心磷脂的脂质体新制剂及其在抗肿瘤药物中的应用 |
Non-Patent Citations (3)
Title |
---|
Lipid composition and grafted PEG affect in vivo activity of liposomal mitoxantrone;ChunLeiLi;《International Journal of Pharmaceutics》;20080613;第362卷(第1-2期);第60-66页 * |
张覃沐.抗肿瘤药物的药理与临床应用.河南医科大学出版社,1999,(第1版),177-178. * |
米托蒽醌免疫脂质体的制备及对前列腺癌的体外作用;徐谊朝;《中国现代医学杂志》;20121231;第22卷(第34期);第18-21页 * |
Also Published As
Publication number | Publication date |
---|---|
US11583508B2 (en) | 2023-02-21 |
EP3821887A4 (en) | 2022-04-20 |
BR112021000452A8 (pt) | 2021-11-03 |
BR112021000452A2 (pt) | 2021-04-06 |
CU20210003A7 (es) | 2021-08-06 |
AU2019301101A1 (en) | 2021-01-28 |
MX2020014107A (es) | 2021-05-27 |
AU2019301101B2 (en) | 2023-10-05 |
JP2021530489A (ja) | 2021-11-11 |
WO2020011189A1 (zh) | 2020-01-16 |
EP3821887B1 (en) | 2024-05-15 |
US20210267915A1 (en) | 2021-09-02 |
CN110711178A (zh) | 2020-01-21 |
CN112384207A (zh) | 2021-02-19 |
CA3105698A1 (en) | 2020-01-16 |
SG11202013236XA (en) | 2021-02-25 |
EP3821887A1 (en) | 2021-05-19 |
KR20210031695A (ko) | 2021-03-22 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN112384207B (zh) | 米托蒽醌脂质体治疗非霍奇金淋巴瘤的用途 | |
AU2021218871B2 (en) | Use of mitoxantrone hydrochloride liposome for treating breast cancer | |
JP2008514721A (ja) | 治療方法 | |
RU2804477C2 (ru) | Применение липосомы митоксантрона для лечения неходжкинской лимфомы | |
CN115427020A (zh) | 盐酸米托蒽醌脂质体的用途 | |
Goldberg et al. | Bolus versus infusion regimens of etoposide and cisplatin in treatment of non-small cell lung cancer: a study of the North Central Cancer Treatment Group | |
AU2019312904A1 (en) | Combination therapy for treating cancer | |
KR20150090091A (ko) | 볼라세르티브와의 병용 요법 | |
US20240024257A1 (en) | Use of mitoxantrone hydrochloride liposome and cyclophosphamide, vincristine and prednisone | |
EP4349325A1 (en) | Use of mitoxantrone hydrochloride liposome in preparation of drugs for treating advanced solid tumors | |
WO2022218393A1 (zh) | 盐酸米托蒽醌脂质体的用途 | |
US20230132982A1 (en) | Use of pyrido[1,2-a]pyrimidinone compound in treating lymphoma | |
WO2023036161A1 (zh) | 米托蒽醌脂质体、硼替佐米和地塞米松治疗多发性骨髓瘤的用途 | |
WO2021224381A1 (en) | Combination therapy for treating cancer | |
CN117940164A (zh) | 米托蒽醌脂质体联合抗血管生成靶向药治疗卵巢癌的用途 | |
WO2010056733A1 (en) | Combined use of bendamustine, doxorubicin and bortezomib for the treatment of multiple myeloma | |
Di Costanzo et al. | Cisplatin and Low-Dose Cytosine Arabinoside in Advanced Cancer |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant | ||
GR01 | Patent grant | ||
TR01 | Transfer of patent right | ||
TR01 | Transfer of patent right |
Effective date of registration: 20240329 Address after: 050035 226 the Yellow River Avenue, Shijiazhuang high tech Industrial Development Zone, Hebei Patentee after: CSPC ZHONGQI PHARMACEUTICAL TECHNOLOGY (SHIJIAZHUANG) Co.,Ltd. Country or region after: China Patentee after: CSPC ZHONGNUO PHARMACEUTICAL (SHIJIAZHUANG) Co.,Ltd. Address before: No. 226, Huanghe Avenue, hi tech Industrial Development Zone, Shijiazhuang City, Hebei Province Post Code: 050035 Patentee before: CSPC ZHONGQI PHARMACEUTICAL TECHNOLOGY (SHIJIAZHUANG) Co.,Ltd. Country or region before: China |